2021
DOI: 10.1007/s10549-021-06269-6
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“… 10 It also has been used for studies evaluating RS as shown in our previous studies. 11 , 12 The database was queried for female patients diagnosed between 2006 and 2018 with ER-positive, pT1-3N0-1aM0 breast cancer who received surgery followed by adjuvant endocrine therapy. Patients were excluded if they had unknown RS or income levels.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“… 10 It also has been used for studies evaluating RS as shown in our previous studies. 11 , 12 The database was queried for female patients diagnosed between 2006 and 2018 with ER-positive, pT1-3N0-1aM0 breast cancer who received surgery followed by adjuvant endocrine therapy. Patients were excluded if they had unknown RS or income levels.…”
Section: Methodsmentioning
confidence: 99%
“…It collected over 34 million cancer cases from more than 1500 CoC-accredited facilities, and it represented 80% of newly diagnosed breast cancer in the US . It also has been used for studies evaluating RS as shown in our previous studies . The database was queried for female patients diagnosed between 2006 and 2018 with ER-positive, pT1-3N0-1aM0 breast cancer who received surgery followed by adjuvant endocrine therapy.…”
Section: Methodsmentioning
confidence: 99%